J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
illi News/10269232

SEOUL, South Korea, June 10, 2024 ~ During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, J INTS BIO provided an update on their Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC). The update was presented during the poster session on June 3rd.

The study, which began in May 2024 and is ongoing, aims to evaluate the safety and efficacy of JIN-A02 in patients with NSCLC. Professor Cho Byoung Chul, a leading researcher in the field of oncology, presented the update and posed with the JIN-A02 poster at the conference.

The latest update reported a partial response (PR) in a patient from Cohort 4 who received a daily dose of 100mg. This is the second PR recorded in the study, with the first being from a patient in an earlier cohort who received a lower dose of 50mg daily. Additionally, this is also the first instance of brain tumor activity being observed in Cohort 4, with a reduction of brain metastasis by 28.6%.

More on illi News

• Chicago: O'Hare International Airport Sets All-Time Passenger Record in July 2025
• The Hidden Triggers of Foreclosure Most Families Don't See Coming
• Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
• 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
• Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark

So far, two patients have shown partial response and three others have stable disease. This includes the patient from Cohort 4 with reduced brain metastasis and two patients from lower cohorts who received lower doses.

The final patient in Cohort 4 is expected to complete their dose-limiting toxicity (DLT) assessment soon and no DLT has been detected thus far. Furthermore, there have been no reports of common side effects such as rash, diarrhea or cardiac toxicity associated with EGFR TKIs use.

J INTS BIO expressed their excitement about sharing these key clinical results at such a prestigious conference attended by global anticancer experts and research and development officials. They also stated that JIN-A02 has potential to be a game changer in improving the lives of patients with EGFR C797S positive NSCLC, for which there is currently no approved treatment. The company plans to enter phase 2 clinical trials by the end of this year.

The next cohort, which will receive a daily dose of 150mg, is set to begin at the end of June. J INTS BIO believes that these results will pave the way for further advancements in the treatment of NSCLC and bring hope to patients and their families.

---

Show All News | Report Violation